NICOLA HANANIA to Inflammation
This is a "connection" page, showing publications NICOLA HANANIA has written about Inflammation.
Connection Strength
1.091
-
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025 Aug; 13(8):687-697.
Score: 0.136
-
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med. 2025 Jun; 13(6):505-516.
Score: 0.134
-
Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS. Chest. 2025 Jul; 168(1):56-66.
Score: 0.132
-
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025 Mar; 13(3):234-243.
Score: 0.132
-
Revisiting Mild Asthma: Current Knowledge and Future Needs. Chest. 2022 01; 161(1):26-39.
Score: 0.105
-
Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017 Feb; 47(2):161-175.
Score: 0.076
-
Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med. 2005 Mar; 11(2):129-34.
Score: 0.033
-
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores. Respir Med. 2025 May; 241:108015.
Score: 0.033
-
The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPD. Chest. 2025 May; 167(5):1346-1355.
Score: 0.033
-
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024 06 27; 390(24):2274-2283.
Score: 0.031
-
Novel Anti-Inflammatory Approaches to COPD. Int J Chron Obstruct Pulmon Dis. 2023; 18:1333-1352.
Score: 0.030
-
Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities. Drugs Aging. 2023 07; 40(7):605-619.
Score: 0.029
-
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023 07 20; 389(3):205-214.
Score: 0.029
-
New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis. Clin Sci (Lond). 2023 05 18; 137(9):727-753.
Score: 0.029
-
Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma. J Allergy Clin Immunol Pract. 2022 02; 10(2):410-419.
Score: 0.027
-
Association of Systemic Inflammation with Depressive Symptoms in Individuals with COPD. Int J Chron Obstruct Pulmon Dis. 2021; 16:2515-2522.
Score: 0.026
-
Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST). J Allergy Clin Immunol Pract. 2020 Nov - Dec; 8(10):3474-3481.
Score: 0.024
-
Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs. Curr Opin Pulm Med. 2018 01; 24(1):50-55.
Score: 0.020
-
Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far? Curr Opin Pulm Med. 2017 01; 23(1):3-11.
Score: 0.019
-
beta-Adrenoceptor inverse agonists in asthma. Curr Opin Pharmacol. 2010 Jun; 10(3):254-9.
Score: 0.012